Surgery for thyroid cancer using autofluorescence imaging
Surgery for Thyroid Cancer With or Without Autofluorescence to Prevent Hypoparathyroidism - a Randomized, Controlled Trial
This study is testing if using special imaging during thyroid cancer surgery can help lower the chances of patients developing low parathyroid hormone levels afterward.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aarhus University Hospital Academic / other |
| Locations | 1 site (Aarhus, Denmark) |
| Trial ID | NCT06222606 on ClinicalTrials.gov |
What this trial studies
This study investigates whether the use of autofluorescence imaging during surgery for thyroid cancer can reduce the risk of developing hypoparathyroidism. Patients undergoing total thyroidectomy or completion hemithyroidectomy will be enrolled to assess the effectiveness of this imaging technique. The goal is to minimize treatment-related complications and improve patient outcomes following thyroid cancer surgery. The study will focus on patients with a confirmed diagnosis of thyroid cancer who are scheduled for surgery.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a suspicion or diagnosis of thyroid cancer who are scheduled for total or completion thyroidectomy.
Not a fit: Patients requiring simultaneous parathyroid surgery or those with severe kidney impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of hypoparathyroidism in patients undergoing thyroid cancer surgery.
How similar studies have performed: While the use of autofluorescence imaging in surgery is a relatively novel approach, preliminary studies have shown promise in reducing complications in similar surgical contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age\>18 years and able to give informed consent. * Suspicion or diagnosis of thyroid cancer. * Planned total thyroidectomy or completion thyroidectomy. * Normocalcemia prior to surgery. Exclusion Criteria: * Planned simultaneous parathyroid surgery. * Treatment with active vitamin D analogues. * eGFR \< 30.
Where this trial is running
Aarhus, Denmark
- Aarhus University Hospital — Aarhus, Denmark, Denmark (Recruiting)
Study contacts
- Study coordinator: Jacob Kinggaard Lilja-Fischer, MD
- Email: jaclil@rm.dk
- Phone: +4540460399
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.